Upamostat potentiates bortezomib cytotoxicity and delays proteasome recovery in bortezomib-resistant malignant lymphoma cells through modulation of the DDI2/NRF1 axis.
Proteasome inhibitors such as bortezomib (BTZ) are potent against hematological malignancies, but acquired resistance remains a major obstacle to durable clinical responses. DNA damage-inducible 1 homolog 2 (DDI2)-mediated processing of nuclear factor erythroid 2-related factor 1 (NRF1) contributes to adaptive proteaso...